Recce Pharmaceuticals (RCE) Stock Price, News & Analysis

Company Overview

Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 630,087 shs
• Average Volume: N/A
• Market Capitalization: A$104.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RCE Stock Analysis - Frequently Asked Questions

How were Recce Pharmaceuticals' earnings last quarter?

Recce Pharmaceuticals Ltd (ASX:RCE) posted its earnings results on Wednesday, February, 27th. The company reported ($0.01) earnings per share for the quarter. Recce Pharmaceuticals had a negative net margin of 741.65% and a positive trailing twelve-month return on equity of 392.94%.

What other stocks do shareholders of Recce Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Recce Pharmaceuticals investors own include ASE Technology (ASX), FlexiGroup Limited (FXL.AX) (FXL), Prima BioMed (IMMP), Mavenir (MVNR), Cronos Group (CRON), Cree (CREE) and Caladrius Biosciences (CLBS).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 7/05/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:RCE
• CIK: N/A
• Web: www.recce.com.au
• Phone: 61 2 8075 4585
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$17.66 million
• Net Margins: -741.65%
• Pretax Margin: N/A
• Return on Equity: 392.94%
• Return on Assets: -238.11%

Debt

• Debt-to-Equity Ratio: -8.52
• Current Ratio: 0.34
• Quick Ratio: 4.81

Sales & Book Value

• Annual Sales: A$5.03 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 13.57
• Book Value: A($0.05) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 231,870,000
• Free Float: N/A
• Market Cap: A$104.34 million
• Optionable: Not Optionable
• Beta: 1.05